Filters
Filters
Funder (7)
Filters
Funder (7)
130 projects, page 1 of 13
ProjectGrantIdFunder
Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic(I-MOVE-COVID-19)101003673EC
Rapid European COVID-19 Emergency research Response(RECoVER)101003589EC
Health Emergency Response in Interconnected Systems(HERoS)101003606EC
Epidemic intelligence to minimize 2019-nCoV’s public health, economic and social impact in Europe(EpiPose)101003688EC
Rapid interaction profiling of 2019-nCoV for network-based deep drug-repurpose learning (DDRL)(RiPCoN)101003633EC
Combating 2019-nCoV: Advanced Nanobiosensing platforms for POC global diagnostics and surveillance(CoNVat)101003544EC
Three Rapid Diagnostic tests (Point-of-Care) for COVID-19 CoronaThree Rapid Diagnostic tests (Point-of-Care) for Coronavirus, improving epidemic preparedness, public health and socio-economic benefits(CoronaDX)101003562EC
FIGHTING-OFF CORONAVIRUS (SARS-CoV-2) WITH BROAD-SPECTRUM ANTIVIRALS: ESTABLISHING ANIMAL VIRAL CHALLENGE MODEL(Fight-nCoV)101003555EC
Swift COronavirus therapeutics REsponse(SCORE)101003627EC
Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus(Solnatide)101003595EC
Antibody therapy against coronavirus (COVID-19)(ATAC)101003650EC
Monoclonal Antibodies against 2019-New Coronavirus(MANCO)101003651EC
Nanobodies and antibodies against 2019-nCoV(CoroNAb)101003653EC
Rapid therapy development through Open nCoronavirus Vaccine Platform(OPENCORONA)101003666EC
Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine(Prevent-nCoV)101003608EC
EXaSCale smArt pLatform Against paThogEns for Corona Virus(EXSCALATE4CoV)101003551EC
Delivering BEACON Caresystem – a ground-breaking ICT-enabled ICU bed-side assistant providing recommenda-tions for critical mechanical ventilation support for better care and reduced costs.(ICU-CARE)804955EC
Next generation decontamination: fast, effective, cheap and non-toxic(DELOX)837148EC
Symptoma, Better Diagnosis for Patients with Rare and Complex Diseases(Symptoma)830017EC
Disinfecting the Stethoscope membrane through a hi-tech UV device(STET CLEAN)828523EC
Preventing Respiratory Events through Proactive Assessment of Respiratory Effort(PREPARE)711269EC
Delivering ECMO-BIOMARKER – a ground-breaking ICT-enabled ECMO Biomarker system providing clinicians with bedside decision support for better care and reduced costs of severe ICU patients(ECMO-BIOMARKER)853850EC
IDENTIFICATION OF NOVEL INHIBITORS AGAINST EMERGING HUMAN CORONAVIRUSES SARS-COV AND MERS-COV FROM HOST CELLULAR TRANSCRIPTIONIC SIGNATURES(COV-SIGN)ANR-14-CE15-0008ANR
SARS-CoV Proteins in Heterologous Viral Infection1P01AI060699-01NIH
A novel strategy for developing a SARS-CoV vaccine1R56AI079424-01A1NIH
A novel strategy for developing a SARS-CoV vaccine5P01AI060699-08NIH
Biological Effects of SARS-CoV Spike Polymorphisms5P01AI060699-03NIH
A SARS-CoV Spike Protein Vaccine5R43AI060098-02NIH
A SARS-CoV Spike Protein Vaccine1R43AI060098-01NIH
Cell culture animal models for SARS-CoV5R21AI059328-02NIH
Cell culture animal models for SARS-CoV1R21AI059328-01NIH
Interaction of SARS-CoV with the Human Airway Epithelium5P01AI060699-05NIH
A SARS-CoV Spike Protein Vaccine1R43AI060098-01NIH
Virus-Like Particle Vaccine for SARS-CoV1R01AI064372-01A1NIH
Role of anti-SARS-CoV T cell response in pathogenesis5R01AI091322-05NIH
Identifying Therapeutic Targets in SARS-CoV Replicase5P01AI060915-04NIH
Virus-Like Particle Vaccine for SARS-CoV5R01AI064372-04NIH
SARS-CoV reverse genetics: expression of small ORFs1R21AI062817-01NIH
Type II Pneumocyte Interactions with SARS-CoV1P01AI059576-01NIH
Role of anti-SARS-CoV T cell response in pathogenesis5R01AI091322-04NIH
Virus-Like Particle Vaccine for SARS-CoV5R01AI064372-03NIH
Role of anti-SARS-CoV T cell response in pathogenesis1R01AI091322-01A1NIH
Development of a vaccine against SARS-CoV5R21AI059217-02NIH
Type II Pneumocyte Interactions with SARS-CoV1P01AI059576-01NIH
Role of anti-SARS-CoV T cell response in pathogenesis5R01AI091322-04NIH
Virus-Like Particle Vaccine for SARS-CoV5R01AI064372-03NIH
Role of anti-SARS-CoV T cell response in pathogenesis1R01AI091322-01A1NIH
Virus-Like Particle Vaccine for SARS-CoV5R01AI064372-02NIH
SARS-CoV reverse genetics: expression of small ORFs5R21AI062817-02NIH
Type II Pneumocyte Interactions with SARS-CoV5P01AI059576-05NIH
Characterization of the SARS-CoV frameshift signal5R01AI064307-03NIH
Deciphering the Role of the Coronavirus Macro Domain in SARS-CoV Infection1F32AI113973-01NIH
Characterization of the SARS-CoV frameshift signal5R01AI064307-02NIH
PPG: SARS-CoV-host cell interactions and vaccine development5P01AI060699-07NIH
Development of peptide-based vaccine against SARS-CoV1U01AI061092-01NIH
PPG: SARS-CoV-host cell interactions and vaccine development2P01AI060699-06A1NIH
Development of peptide-based vaccine against SARS-CoV5U01AI061092-04NIH
Development of peptide-based vaccine against SARS-CoV5U01AI061092-02NIH
Development of peptide-based vaccine against SARS-CoV5U01AI061092-05NIH
Development of peptide-based vaccine against SARS-CoV5U01AI061092-03NIH
Human Antibodies and Targeted Vaccines Against SARS-CoV5U01AI061318-03NIH
Yeast Based Assays for Chemical Screens Against SARS-CoV Targets3R21NS063854-01S1NIH
SARS-CoV Mediated Modulation of Innate Immunity1F32AI066542-01NIH
Human Antibodies and Targeted Vaccines Against SARS-CoV5U01AI061318-02NIH
Task A14 MOUSE MODELS FOR SARS-CoV: EVALUATION OF VACCINES AND THERAPEUTICS272201000039I-0-27200002-1NIH
SARS-CoV Mediated Modulation of Innate Immunity5F32AI066542-02NIH
SARS-CoV Mediated Modulation of Innate Immunity5F32AI066542-03NIH
Human Antibodies and Targeted Vaccines Against SARS-CoV5U01AI061318-05NIH
SARS-CoV Pathogenic Mechanisms in Senescent Mice1R01AI075297-01A1NIH
Human Antibodies and Targeted Vaccines Against SARS-CoV1U01AI061318-01NIH
SARS-CoV Pathogenic Mechanisms in Senescent Mice5R01AI075297-03NIH
Rewiring SARS-CoV Genome Organization and Pathogenesis5P01AI059443-02NIH
SARS-CoV Pathogenic Mechanisms in Senescent Mice5R01AI075297-05NIH
SARS-CoV Pathogenic Mechanisms in Senescent Mice5R01AI075297-04NIH
SARS-CoV Pathogenic Mechanisms in Senescent Mice5R01AI075297-02NIH
Human Antibodies and Targeted Vaccines Against SARS-CoV5U01AI061318-04NIH
Rewiring SARS-CoV Genome Organization and Pathogenesis5P01AI059443-05NIH
Modeling viral entry and its inhibition using SARS-CoV1R01AI074986-01A1NIH
Determining SARS-CoV host gene requirements by mutagenesis and RNA interface5R21AI071109-02NIH
Evaluation of SARS-CoV 2'O Methyltransferase Mutants1F32AI102561-01A1NIH
Modeling viral entry and its inhibition using SARS-CoV5R01AI074986-02NIH
Determining SARS-CoV host gene requirements by mutagenesis and RNA interface1R21AI071109-01A1NIH
Modeling viral entry and its inhibition using SARS-CoV5R01AI074986-04NIH
Evaluation of SARS-CoV 2'O Methyltransferase Mutants5F32AI102561-02NIH
SARS-CoV Transcription Network Remodeling and the Attenuation of Pathogenesis1F32AI080148-01NIH
Modeling viral entry and its inhibition using SARS-CoV5R01AI074986-05NIH
SARS-CoV Transcription Network Remodeling and the Attenuation of Pathogenesis5F32AI080148-03NIH
SARS-CoV S Protein Receptor-binding Domain-based Vaccines5R01AI068002-02NIH
SARS-CoV S Protein Receptor-binding Domain-based Vaccines5R01AI068002-03NIH
SARS-CoV S Protein Receptor-binding Domain-based Vaccines5R01AI068002-04NIH
Yeast Based Assays for Chemical Screens Against SARS-CoV Targets1R21NS063854-01NIH
SARS-CoV Transcription Network Remodeling and the Attenuation of Pathogenesis5F32AI080148-02NIH
SARS-CoV S Protein Receptor-binding Domain-based Vaccines5R01AI068002-02NIH
SARS-CoV S Protein Receptor-binding Domain-based Vaccines5R01AI068002-03NIH
SARS-CoV S Protein Receptor-binding Domain-based Vaccines5R01AI068002-04NIH
Development of a plant-derived virus-like particle vaccine against SARS-CoV1R21AI073928-01A2NIH
Development of a plant-derived virus-like particle vaccine against SARS-CoV5R21AI073928-02NIH
ACE2 as a target for pulmonary hypertension therapeutics5RC1HL099980-02NIH
Biology of ACE2 activity in the airway epithelium5P01AI060699-09NIH
ACE2, Brain, Gut Dysbiosis in Pulmonary Hypertension2R01HL102033-06NIH
ACE2 as a target for pulmonary hypertension therapeutics1RC1HL099980-01NIH
ACE2, Brain, Gut Dysbiosis in Pulmonary Hypertension5R01HL102033-07NIH
ACE2, Brain, Gut Dysbiosis in Pulmonary Hypertension5R01HL102033-08NIH
ACE2 Safety and Mechanism in Treatment of Pulmonarv Arterial Hypertension/Loyd5P01HL108800-02NIH
The host response to highly pathogenic influenza virus1037883NHMRC
IDENTIFICATION OF NOVEL INHIBITORS AGAINST EMERGING HUMAN CORONAVIRUSES SARS-COV AND MERS-COV FROM HOST CELLULAR TRANSCRIPTIONIC SIGNATURES(COV-SIGN)ANR-14-CE15-0008ANR
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV5R01AI132178-02NIH
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV1R01AI132178-01NIH
A MERS-CoV Receptor Decoy2R44AI114023-02A1NIH
A MERS-CoV Receptor Decoy5R44AI114023-03NIH
A MERS-CoV Receptor Decoy1R43AI114023-01NIH
P2: Targeting immunophilin- and MAPK-associated pathways to inhibit MERS-CoV replication and prevent lung injury319808243DFG
A mucosally targeted MERS-CoV vaccine produced in plants1R43AI122551-01A1NIH
Small Molecule Protease Inhibitors against MERS-CoV1R01AI130092-01A1NIH
Development of a subunit vaccine for MERS-CoV and other emerging coronaviruses1R21AI135373-01A1NIH
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine1R21AI114264-01A1NIH
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine5R21AI114264-02NIH
Investigating MERS-CoV NS4b as a modulator of the host antiviral response in the nucleus1F31AI126673-01A1NIH
Investigating MERS-CoV NS4b as a modulator of the host antiviral response in the nucleus5F31AI126673-02NIH
Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis5R01AI110700-04NIH
A novel nanobody with good druggability to prevent and treat MERS-CoV infection5R21AI128311-02NIH
Ecology of MERS-CoV in camels, humans, and wildlife in Ethiopia1816064NSF
Rational design and evaluation of novel mRNA vaccines against MERS-CoV1R01AI137472-01NIH
Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis5R01AI110700-03NIH
A novel nanobody with good druggability to prevent and treat MERS-CoV infection1R21AI128311-01NIH
Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis5R01AI110700-02NIH
Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis1R01AI110700-01A1NIH
Conserved RNA Secondary Structures in three Betacoronaviruses: MHV, BCoV, and MERS-CoV5R21AI121807-02NIH
A one health approach to the investigation and control of MERS-CoV among camel and human populations in Jordan as a potential model for the regionMR/P02551X/1RCUK
Conserved RNA Secondary Structures in three Betacoronaviruses: MHV, BCoV, and MERS-CoV1R21AI121807-01NIH
130 projects, page 1 of 13
Last index information